Atherosclerosis of Femoral Artery, Superficial Femoral Artery Lesions
Conditions
Keywords
Superficial femoral artery, Peripheral arterial disease, Atherosclerosis, Intermittent Claudication, Vascular Diseases, Cardiovascular Diseases
Brief summary
This is an initial evaluation of the 480 Biomedical Bioresorbable Scaffold System for the treatment of subjects with de novo native superficial femoral artery lesions.
Interventions
DEVICE480 Biomedical Bioresorbable Scaffold System
480 Biomedical Bioresorbable Scaffold System
Sponsors
480 Biomedical
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age \>/= 18 years 2. De novo stenotic lesion(s) in the superficial femoral artery located at least 1cm distal to the femoral bifurcation and \> 3 cm above the knee joint 3. Lifestyle-limiting claudication defined as symptomatic subjects with Rutherford Becker Category 2-3 4. Target lesion native reference vessel diameter 4.6 - 6.0 mm by on-line QVA; target lesion native reference vessel diameter less than 5.0 mm only if lesion residual stenosis is ≤ 25% 5. Lesion length: up to a maximum that can be covered by one 100mm scaffold 6. Target lesion \> 50% stenosis or total occlusion 7. Undisturbed flow to the foot via at least 2 patent infrapopliteal vessel on the treated side with one vessel free from \> 50% stenosis to the ankle joint 8. Patent common and external iliac; TASC A & B lesions may be successfully treated (\<30% residual stenosis) at the time of the index procedure 9. The study patient or the study patient's legal representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by the Human Research Ethics Committee (HREC) of the respective clinical site 10. The study patient agrees to comply with all required post-procedure follow-up visits
Exclusion criteria
1. Previously implanted stent(s) or stent graft(s) in the target lesion 2. Previous endovascular treatment of the target lesion 3. Femoral access in the target limb within 30 days of study procedure 4. Target lesion residual stenosis \> 30% after pre-dilatation with nominally sized balloon 5. Severely calcified lesions as determined by a balloon deformity during dilatation with a nominally sized balloon inflated at nominal pressure. 6. Acute embolic complication at the trifurcation following pre-dilatation not resolved by aspiration 7. Target vessel contains acute thrombus 8. Aneurysm in target vessel 9. Critical limb ischemia defined as Rutherford-Becker Category 4-6 10. Intolerance, or allergies which cannot be adequately pre-medicated, to the following: aspirin, clopidogrel or ticlopidine, heparin, any scaffold components, contrast agents 11. Life expectancy of less than 12 months 12. Pregnancy or breast feeding (negative pregnancy test within 7 days required in females of child bearing potential) 13. Non-atherosclerotic lesion (e.g. vasculitis or Berger's disease) 14. Renal insufficiency (serum creatinine level \> 220 µmol/L, or subject is on dialysis) 15. Immunocompromised 16. Active systemic infection or lower limb infection of any nature 17. WBC \< 3,000 cells/mm3 18. Myocardial infarction within the past 1 month 19. Stroke within 3 months 20. Un-controlled Atrial-Fibrillation 21. Currently participating in an investigational drug or another device study. Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Major adverse events at 6 months post procedure | 6 Months |
Secondary
| Measure | Time frame |
|---|---|
| Major adverse events at 3, 12 months and 24 months post procedure | 3, 12 & 24 Months |
| Patency in the treated vessel at 1, 3, 6, 12 and 24 months post procedure | 1, 3, 6, 12, 24 Months |
| Change in Rutherford Becker Category at 1, 3, 6,12 and 24 months post procedure | 1, 3, 6, 12, 24 Months |
| Major adverse events at 1 month post procedure | 1 Month |
| Ankle-Brachial Index (ABI) at 1, 3, 6, 12, and 24 months post procedure | 1, 3, 6, 12, 24 Months |
| Clinically driven TLR at 3, 12 and 24 months post procedure | 3,12, 24 Months |
| Walking Impairment Questionnaire | 1, 3, 6, 12, 24 Months |
Countries
Australia, Austria, Germany, New Zealand
Outcome results
None listed